Drugs / HER-2/neu peptide vaccine
last change Dec 2014 re-read 2 minutes ago

HER-2/neu peptide vaccine

Vaccine

Developed for
HER2 positive breast carcinoma
Investigated by
National Cancer Institute (NCI) · University of Washington

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00791037 Oct 2008 → Jul 2013 HER2 positive breast carcinoma, male breast carcinoma University of Washington Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HER-2/neu peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00791037
Modality Vaccine “HER2/neu peptide vaccineNCT00791037
Route Other “intradermally (ID)” NCT00791037